Apres-demain SA
About Debiopharm Investment / Debiopharm Investment SA pursues a mission of preserving, diversifying and supporting the sustainable growth of Debiopharm Group, a biopharmaceutical development company based in Lausanne (Switzerland), through a comprehensive investment strategy centered on three areas of activity: Finance (portfolio management, currency hedging), Real Estate (residential and commercial) and Private Equity. The Private Equity team focuses primarily on investment diversification, managing a portfolio of funds and direct equity investments, as minority shareholders, in the capital of pioneering start-ups as well as small and medium-sized European companies. Our entrepreneurial background, as well as our willingness and capacity to be long-term partners alongside the teams in which we invest, are the established pillars of our commitment.
Investments
| Type of firm | Corporate Subsidiary |
|---|
| Investment Stages | Buyout - Buyin, Expansion - Development Capital |
|---|
| Industrial Sectors | All |
|---|
| Geographical Focus | France, Switzerland, Western Europe |
|---|
| Type of financing | Equity Financing, Minority Equity |
|---|
Company Profile
| Number of Employees in Switzerland | 20 |
|---|
| Number of Portfolio Companies | 20 |
|---|
| Examples of Portfolio Companies | Haut-Lac International bilingual school, Coorpacademy |
|---|
| Size of Investment | From CHF 5m to 20m depending on investment stages |
|---|